Eiko LifeSciences Limited reported a 106% year-on-year increase in net profit to ₹358.11 lakh for the financial year ended March 31, 2026. Revenue from operations rose 30% to ₹4,212.68 lakh, driven by the speciality chemicals and pharma intermediates segment. The board approved the audited standalone and consolidated financial results at its meeting on May 26, 2026.

The statutory auditor, PSV Jain & Associates, issued an unmodified opinion on the financial results. The board also appointed M/s NP Rajput & Co as the internal auditor for FY27.

Financial Performance

The company’s standalone total revenue for FY26 stood at ₹4,425.61 lakh, compared to ₹3,351.58 lakh in the previous year. Total expenses increased to ₹3,954.31 lakh from ₹3,153.88 lakh. Basic earnings per share (EPS) for the year doubled to ₹2.60 from ₹1.34 in the prior year.

On a consolidated basis, net profit for FY26 surged 130% to ₹532.47 lakh from ₹231.86 lakh in FY25. Consolidated revenue from operations grew 40% to ₹5,270.66 lakh. The company’s subsidiary, Eikovivify Logistics Private Limited, commenced operations during the year, contributing to the logistics services segment.

Capital Allocation

Pursuant to shareholder approval in January 2026, the company allotted 6,25,000 equity shares and 29,50,000 warrants. The equity shares were issued at ₹55 per share, including a premium of ₹45. The proceeds strengthened the balance sheet, with cash and cash equivalents increasing to ₹1,355.16 lakh as of March 31, 2026.

The trading window for directors and designated persons, which closed on April 1, 2026, will reopen 48 hours after the declaration of the financial results.

Eiko lifesciences Limited has formally notified BSE Limited about its status regarding SEBI's regulatory framework for large corporate debt securities. The company submitted its annual disclosure on April 09, 2026, clarifying its position under the Securities and Exchange Board of India's guidelines for fund raising through debt instruments.

Regulatory Compliance Status

The company has confirmed that as of March 31, 2026, it does not meet the criteria to be classified as a Large Corporate under SEBI regulations. This determination is based on the provisions outlined in SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, along with its subsequent amendments.

SEBI Framework Non-Applicability

Since Eiko Lifesciences Limited does not qualify as a Large Corporate under the specified criteria, the regulatory framework for fund raising by issuance of debt securities by large corporates does not apply to the company. This exemption has significant implications for the company's compliance obligations.

The non-applicability means that Eiko Lifesciences Limited is not required to comply with the specific disclosure requirements mandated for large corporates under this framework. The company is therefore exempt from filing both initial disclosures and annual disclosures that would otherwise be mandatory for entities classified as Large Corporates.

Regulatory References

The disclosure submission references multiple SEBI circulars that govern the large corporate debt framework:

• SEBI Circular SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023
• SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021
• SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018

Corporate Governance

The disclosure was signed by Chintan Doshi, Company Secretary and Compliance Officer, with membership number A 36190. The submission was digitally signed on April 09, 2026, demonstrating the company's commitment to maintaining proper corporate governance standards and regulatory compliance.